Japanese Society for Cancer of the Colon and Rectum (JS']JSCCR) guidelines 2016 for the treatment of colorectal cancer

被引:690
作者
Watanabe, Toshiaki [1 ]
Muro, Kei [2 ]
Ajioka, Yoichi [3 ]
Hashiguchi, Yojiro [4 ]
Ito, Yoshinori [5 ]
Saito, Yutaka [6 ]
Hamaguchi, Tetsuya [7 ]
Ishida, Hideyuki [8 ]
Ishiguro, Megumi [9 ]
Ishihara, Soichiro [1 ]
Kanemitsu, Yukihide [10 ]
Kawano, Hiroshi [11 ]
Kinugasa, Yusuke [12 ]
Kokudo, Norihiro [13 ]
Murofushi, Keiko [14 ]
Nakajima, Takako [15 ]
Oka, Shiro [16 ]
Sakai, Yoshiharu [17 ]
Tsuji, Akihito [18 ]
Uehara, Keisuke [19 ]
Ueno, Hideki [20 ]
Yamazaki, Kentaro [21 ]
Yoshida, Masahiro [22 ]
Yoshino, Takayuki [23 ]
Boku, Narikazu [7 ]
Fujimori, Takahiro [24 ]
Itabashi, Michio [25 ]
Koinuma, Nobuo [26 ]
Morita, Takayuki [27 ]
Nishimura, Genichi [28 ]
Sakata, Yuh [29 ]
Shimada, Yasuhiro [30 ]
Takahashi, Keiichi [31 ]
Tanaka, Shinji [32 ]
Tsuruta, Osamu [33 ]
Yamaguchi, Toshiharu [34 ]
Yamaguchi, Naohiko [35 ]
Tanaka, Toshiaki [1 ]
Kotake, Kenjiro [36 ]
Sugihara, Kenichi [37 ]
机构
[1] Univ Tokyo, Grad Sch Med, Dept Surg Oncol, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138655, Japan
[2] Aichi Canc Ctr Hosp, Dept Clin Oncol, Nagoya, Aichi, Japan
[3] Niigata Univ, Grad Sch Med & Dent Sci, Div Mol & Diagnost Pathol, Niigata, Japan
[4] Teikyo Univ, Dept Surg, Tokyo, Japan
[5] Natl Canc Ctr, Dept Radiat Oncol, Tokyo, Japan
[6] Natl Canc Ctr, Endoscopy Div, Tokyo, Japan
[7] Natl Canc Ctr, Div Gastrointestinal Med Oncol, Tokyo, Japan
[8] Saitama Med Univ, Dept Digest Tract & Gen Surg, Saitama Med Ctr, Saitama, Japan
[9] Tokyo Med & Dent Univ, Dept Translat Oncol, Grad Sch, Tokyo, Japan
[10] Natl Canc Ctr, Colorectal Surg Div, Tokyo, Japan
[11] St Marys Hosp, Dept Gastroenterol, Fukuoka, Japan
[12] Shizuoka Canc Ctr, Dept Colon & Rectal Surg, Shizuoka, Japan
[13] Univ Tokyo, Grad Sch Med, Hepatobiliary Pancreat Surg Div, Artificial Organ & Transplantat Div,Dept Surg, Tokyo, Japan
[14] Japanese Fdn Canc Res, Canc Inst Hosp, Dept Radiat Oncol, Tokyo, Japan
[15] St Marianna Univ, Dept Clin Oncol, Sch Med, Kawasaki, Kanagawa, Japan
[16] Hiroshima Univ Hosp, Gastroenterol & Metab, Hiroshima, Japan
[17] Kyoto Univ, Dept Surg, Kyoto, Japan
[18] Kagawa Univ, Dept Clin Oncol, Fac Med, Takamatsu, Kagawa, Japan
[19] Nagoya Univ, Div Surg Oncol, Dept Surg, Grad Sch Med, Nagoya, Aichi, Japan
[20] Natl Def Med Coll, Dept Surg, Saitama, Japan
[21] Shizuoka Canc Ctr, Div Gastrointestinal Oncol, Shizuoka, Japan
[22] Int Univ Hlth & Welf, Chemotherapy Res Inst, Dept Hemodialysis & Surg, Ichikawa, Japan
[23] Natl Canc Ctr Hosp East, Dept Gastroenterol & Gastrointestinal Oncol, Chiba, Japan
[24] Shinko Hosp, Diagnost Pathol Ctr, Kobe, Hyogo, Japan
[25] Tokyo Womens Med Univ, Inst Gastroenterol, Dept Surg, Tokyo, Japan
[26] Tohoku Med & Pharmaceut Univ, Dept Hlth Adm & Policy, Sendai, Miyagi, Japan
[27] Aomori Prefectural Cent Hosp, Dept Surg, Ctr Canc, Aomori, Japan
[28] Japanese Red Cross Kanazawa Hosp, Dept Surg, Kanazawa, Ishikawa, Japan
[29] Misawa City Hosp, CEO, Misawa, Japan
[30] Kochi Hlth Sci Ctr, Div Clin Oncolgy, Kochi, Japan
[31] Komagome Hosp, Dept Surg, Tokyo Metropolitan Canc & Infect Dis Ctr, Tokyo, Japan
[32] Hiroshima Univ Hosp, Dept Endoscopy, Hiroshima, Japan
[33] Kurume Univ, Div GI Endoscopy, Sch Med, Fukuoka, Japan
[34] Japanese Fdn Canc Res, Canc Inst Hosp, Dept Surg Gastroenterol, Tokyo, Japan
[35] Lib SEIREI SAKURA Citizen Hosp, Sakura, Chiba, Japan
[36] Tochigi Canc Ctr, Dept Surg, Utsunomiya, Tochigi, Japan
[37] Koujinkai Daiichi Hosp, Tokyo, Japan
关键词
Colorectal cancer; Guideline; Surgery; Chemotherapy; Endoscopy; Radiotherapy; PHASE-III TRIAL; TOTAL MESORECTAL EXCISION; FLUOROURACIL PLUS LEUCOVORIN; INTERVAL HEPATIC RESECTION; SINGLE-AGENT PANITUMUMAB; FRAIL ELDERLY-PATIENTS; LYMPH-NODE METASTASIS; HIGH-DOSE LEUCOVORIN; INTENSIVE FOLLOW-UP; WILD-TYPE KRAS;
D O I
10.1007/s10147-017-1101-6
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Japanese mortality due to colorectal cancer is on the rise, surpassing 49,000 in 2015. Many new treatment methods have been developed during recent decades. The Japanese Society for Cancer of the Colon and Rectum Guidelines 2016 for the treatment of colorectal cancer (JSCCR Guidelines 2016) were prepared to show standard treatment strategies for colorectal cancer, to eliminate disparities among institutions in terms of treatment, to eliminate unnecessary treatment and insufficient treatment, and to deepen mutual understanding between health-care professionals and patients by making these Guidelines available to the general public. These Guidelines were prepared by consensus reached by the JSCCR Guideline Committee, based on a careful review of the evidence retrieved by literature searches, and in view of the medical health insurance system and actual clinical practice settings in Japan. Therefore, these Guidelines can be used as a tool for treating colorectal cancer in actual clinical practice settings. More specifically, they can be used as a guide to obtaining informed consent from patients and choosing the method of treatment for each patient. As a result of the discussions held by the Guideline Committee, controversial issues were selected as Clinical Questions, and recommendations were made. Each recommendation is accompanied by a classification of the evidence and a classification of recommendation categories based on the consensus reached by the Guideline Committee members. Here we present the English version of the JSCCR Guidelines 2016.
引用
收藏
页码:1 / 34
页数:34
相关论文
共 147 条
  • [31] Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer
    Cunningham, D
    Pyrhönen, S
    James, RD
    Punt, CJA
    Hickish, TF
    Heikkila, R
    Johannesen, TB
    Starkhammar, H
    Topham, CA
    Awad, L
    Jacques, C
    Herait, P
    [J]. LANCET, 1998, 352 (9138) : 1413 - 1418
  • [32] Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer
    de Gramont, A
    Figer, A
    Seymour, M
    Homerin, M
    Hmissi, A
    Cassidy, J
    Boni, C
    Cortes-Funes, H
    Cervantes, A
    Freyer, G
    Papamichael, D
    Le Bail, N
    Louvet, C
    Hendler, D
    de Braud, F
    Wilson, C
    Morvan, F
    Bonetti, A
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (16) : 2938 - 2947
  • [33] Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: A French intergroup study
    deGramont, A
    Basset, JF
    Milan, C
    Rougier, P
    Bouche, O
    Etienne, PL
    Morvan, F
    Louvet, C
    Guillot, C
    Francois, E
    Bedenne, L
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (02) : 808 - 815
  • [34] Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer: The PRIME Study
    Douillard, Jean-Yves
    Siena, Salvatore
    Cassidy, James
    Tabernero, Josep
    Burkes, Ronald
    Barugel, Mario
    Humblet, Yves
    Bodoky, Gyoergy
    Cunningham, David
    Jassem, Jacek
    Rivera, Fernando
    Kocakova, Ilona
    Ruff, Paul
    Blasinska-Morawiec, Maria
    Smakal, Martin
    Canon, Jean-Luc
    Rother, Mark
    Oliner, Kelly S.
    Wolf, Michael
    Gansert, Jennifer
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (31) : 4697 - 4705
  • [35] Multicenter phase III study of uracil/tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer
    Douillard, JY
    Hoff, PM
    Skillings, JR
    Eisenberg, P
    Davidson, N
    Harper, P
    Vincent, MD
    Lembersky, BC
    Thompson, S
    Maniero, A
    Benner, SE
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (17) : 3605 - 3616
  • [36] Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial
    Douillard, JY
    Cunningham, D
    Roth, AD
    Navarro, M
    James, RD
    Karasek, P
    Jandik, P
    Iveson, T
    Carmichael, J
    Alakl, M
    Gruia, G
    Awad, L
    Rougier, P
    [J]. LANCET, 2000, 355 (9209) : 1041 - 1047
  • [37] ENKER WE, 1995, J AM COLL SURGEONS, V181, P335
  • [38] Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer:: The Gruppo Oncologico Nord Ovest
    Falcone, Alfredo
    Ricci, Sergio
    Brunetti, Isa
    Pfanner, Elisabetta
    Allegrini, Giacomo
    Barbara, Cecilia
    Crino, Lucio
    Benedetti, Giovanni
    Evangelista, Walter
    Fanchini, Laura
    Cortesi, Enrico
    Picone, Vincenzo
    Vitello, Stefano
    Chiara, Silvana
    Granetto, Cristina
    Porcile, Gianfranco
    Fioretto, Luisa
    Orlandini, Cinzia
    Andreuccetti, Michele
    Masi, Gianluca
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (13) : 1670 - 1676
  • [39] Follow-up of patients with curatively resected colorectal cancer: a practice guideline
    Figueredo, A
    Rumble, RB
    Maroun, J
    Earle, CC
    Cummings, B
    McLeod, R
    Zuraw, L
    Zwaal, C
    [J]. BMC CANCER, 2003, 3 (1)
  • [40] DETECTION AND SURVEILLANCE OF COLORECTAL-CANCER
    FLEISCHER, DE
    GOLDBERG, SB
    BROWNING, TH
    COOPER, JN
    FRIEDMAN, E
    GOLDNER, FH
    KEEFFE, EB
    SMITH, LE
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1989, 261 (04): : 580 - 585